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Background: Hepatic glycogen storage diseases (GSDs) are a group of rare genetic 
disorders in which glycogen cannot be metabolized to glucose in the liver because of 
enzyme deficiencies along the glycogenolytic pathway. GSDs are well‐recognized 
diseases that can occur without the full spectrum, and with overlapping in symptoms.
Methods: We analyzed a cohort of 125 patients with suspected hepatic GSD through 
a next‐generation sequencing (NGS) gene panel in Ion Torrent platform. New vari-
ants were analyzed by pathogenicity prediction tools.
Results: Twenty‐seven new variants predicted as pathogenic were found between 
63 variants identified. The most frequent GSD was type Ia (n = 53), followed by Ib 
(n = 23). The most frequent variants were p.Arg83Cys (39 alleles) and p.Gln347* 
(14 alleles) in G6PC gene, and p.Leu348Valfs (21 alleles) in SLC37A4 gene.
Conclusions: The study presents the largest cohort ever analyzed in Brazilian pa-
tients with hepatic glycogenosis. We determined the clinical utility of NGS for di-
agnosis. The molecular diagnosis of hepatic GSDs enables the characterization of 
diseases with similar clinical symptoms, avoiding hepatic biopsy and having faster 
results.
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1 |  INTRODUCTION
Hepatic glycogen storage diseases (GSDs) are a group of in-
born errors of metabolism that include 11 different diseases 
caused by defects in glycogenolytic pathway. These defects 
are caused by pathogenic variants that result in enzymatic 
deficiencies for glycogen breakdown or synthesis, or prob-
lems in proteins that regulate glycogen metabolism. The 
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consequence is accumulation of glycogen in tissues, espe-
cially in liver (Chen & Zhong, 2013).
The general GSD frequency is 1 in 2,000–43,000 and 
their distribution is pan‐ethnic (Özen, 2007; Vega et al., 
2016). Some forms of GSDs are underestimated due to mild 
symptoms, rare occurrence, or difficult diagnostic methods. 
Symptoms may range from neonatal to almost asymptomatic, 
and the age of onset, severity, morbidity, mortality, and prog-
nosis are dependent of causal variants (Kishnani et al., 2014, 
2010; Laforêt, Weinstein, & Smit, 2012; Özen, 2007; Wang 
et al., 2012). The main clinical symptoms are hypoglycemia 
and hepatomegaly, and long‐term complications are frequent 
(Burda & Hochuli, 2015).
Different types of GSDs can be clinically indistinguish-
able and need liver biopsy, an invasive method. In this aim, 
the molecular diagnosis using blood samples generates an ac-
curate diagnosis and allows prognosis and genetic counseling 
(Choi et al., 2017; Davit‐Spraul et al., 2011). Similar diseases 
in clinical symptoms, metabolic routes, or genetic features 
are a challenge to diagnose. In this aim, next‐generation se-
quencing (NGS) is an important tool to determine the cause 
of the disease with accuracy and efficacy, allowing a more 
suitable treatment.
Only two previous studies have characterized 13 patients 
with GSD Ia and Ib in Brazilian population (Carlin, Scherrer, 
Tommaso, Bertuzzo, & Steiner, 2013; Reis et al., 2001).
In the present study, we describe the results of variant 
analysis in a cohort of 125 patients with hepatic GSD sus-
pected diagnosis by NGS.
2 |  MATERIAL AND METHODS
This study was approved by the Research Ethics Committee 
of Hospital de Clínicas de Porto Alegre (project no. 15‐0556), 
and all patients and guardians provided written informed 
consent for participation.
Were analyzed 125 patients with clinical symptoms of he-
patic GSD. Blood samples were collected in EDTA vacuum 
container. DNA was extracted with Easy‐DNA Purification 
kit (Thermo Fisher). DNA samples were quantificated in 
NanoDrop 1000 (Thermo Fisher) and through Qubit dsDNA 
HS Assay Kit (Thermo Fisher).
The gene panel amplicon was designed with Ion Ampliseq 
Designer software (Thermo Fisher), and included the exons 
and flanking 40 bp into introns of 11 genes involved in he-
patic GSD (Table 1). The sequencing was performed in Ion 
Torrent PGM platform (Applied Biosystems), based in PCR 
amplification with minimal coverage of 200X. Base calling 
and sequence read quality assessments were performed using 
Torrent Suite 5.0.5. Alignment of the sequence reads to a ref-
erence human genome (GRCh37.p13) was performed using 
IonStates alignment.
The softwares Enlis Genome Research (LLC), Variant 
Effect Predictor (Ensembl), Ion Reporter (Thermo Fisher) 
and Varstation® (Varstation) were used to detect and clas-
sify variants. To determine the variants causing disease, the 
following were considered: ACMG guideline (Richards et 
al., 2015); allele frequency under 1% in the 1,000 Genomes 
Project (Sabeti, 2015); location in exon or borderlines; im-
pact in the protein (missense, nonsense or splicing sites); 
and pathogenicity by predictors SIFT and Polyphen 2. 
For score of pathogenicity predictions in missense novel 
variants were used the softwares Polyphen 2 (Adzhubei et 
al., 2010), SIFT (Vaser, Adusumalli, Leng, Sikic, & Ng, 
2016), PROVEAN (Choi, Sims, Murphy, Miller, & Chan, 
2012), Mutation Teaster (Schwarz, Cooper, Schuelke, & 
Seelow, 2014), Pmut 2017 (López‐Ferrando, Gazzo, Cruz, 
Orozco, & Gelpí, 2017), SNP&Go (Profiti, Martelli, & 
Casadio, 2017), PhDSNP (Capriotti & Fariselli, 2017), 
Panther (Thomas et al., 2003), SNAP2 (Hecht, Bromberg, 
& Rost, 2015) and MutPred (Pejaver et al., 2017). For 
splice site variants, Genescan (Burge & Karlin, 1997) and 
MaxEntScan were used (Yeo & Burge, 2003).
Validations of NGS results were realized by Sanger se-
quencing in patients and in parents when the sample was 
available. The unbiased capture and deep coverage of each 
coding exon and adjacent intronic region of all genes in this 
panel ensure accuracy of variant detection.
3 |  RESULTS
We analyzed 125 patients with clinical suspicion of hepatic 
GSD. All samples were successfully sequenced. We found 
63 different variants in 110 families, and 27 of those were 
new variants (Tables 2 and Appendix S1).
Seventy‐five patients are men. The patients included in 
the study are from all Brazilian regions: 63 from the south-
east (SP n = 48, RJ n = 2, MG n = 10, ES n = 3), 50 from the 
south (RS n = 46, SC n = 4), eight from the northeast (BA 
n = 2, CE n = 3, PB n = 3), two from the Midwest (DF = 1, 
MT n = 1) and two from the north (PA n = 2) (Appendix S1).
Both pathogenic variants were identified in 118 patients 
confirming the molecular diagnosis of hepatic GSD. For two 
patients, only one variant was found (patients 84 and 85). 
In five patients, no variant was identified (Appendix S1). 
All identified variants were confirmed by Sanger sequenc-
ing and investigated in literature or databanks (Tables 2 and 
Appendix S1).
Eight families included in this study had multiple affected 
individuals. For patients 5, 11, and 12 (11 and 12 are sisters), 
their parents reported consanguinity (Appendix S1). These 
information were considered while counting alleles.
Sixty‐three alleles were identified, in which 26 are mis-
sense variants (41.2%), 16 are nonsense variants (25.3%), six 
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are splice site variants (9.5%), 11 deletions (17.4%), three in-
sertions (4.7%) and one duplication (1.5%) (Table 2).
Among the 125 patients analyzed, 53 were genetically di-
agnosed with GSD Ia (42%), 23 with GSD Ib (18%), 14 with 
GSD III (11%), two with GSD VI (1.6%), 16 GSD IXa (12%), 
six with GSD IXb (4.8%), six with GSD IXc (4.8%), and five 
were not diagnosed (4%) (Appendix S1).
The most frequent variants in patients were p.Arg83Cys, 
observed in 39 alleles (18.5%), and p.Gln347* present in 
14 alleles (6.6%), both in G6PC gene, causing GSD Ia. The 
other frequent variant, p.Leu348Valfs in SLC37A4 gene, was 
observed in 10% of alleles causing GSD Ib.
Variants not described in the literature were evaluated 
for protein impact by nine in silico pathogenicity predic-
tion algorithms. All new missense variants were predicted 
as pathogenic. In the bioinformatics analyses of new splice 
site variants, all were confirmed to modify the exon–intron 
structures in different forms importantly, showing sufficient 
entropy forces to perform the incorrect splicing.
4 |  DISCUSSION
This is one of the largest screening of variants causing the 
different forms of GSDs in patients, including 125 patients 
and describing 63 different variants, of which 27 are novel.
The GSD Ia and GSD Ib represent 60% of the analyzed 
patients. In other analyzed cohorts, Vega et al. (2016) re-
ported more than three‐quarters of patients who had GSD III 
or GSD IXa (39% of each type), and Özen (2007) found GSD 
type IXa as the most common form of the disease. These data 
reflect the differences among populations, the existence of 
private pathogenic variants, and the differences in prevalence 
of variants in GSDs.
GSD type Ia is the most widely distributed. The most 
frequent pathogenic variant found in this work was p.Arg-
83Cys, present in 18.5% of all patients and 39% of alleles in 
GSD Ia patients. This is one of the most important variant 
found around the world in patients with GSD Ia (Chou & 
Mansfield, 2008; Matern, Seydewitz, Bali, Lang, & Chen, 
2002). This variant in G6PC is in the active center of the 
enzyme G6Pase and presented no detectable activity in tran-
sient expression assays (Lei, Shelly, Pan, Sidbury, & Chou, 
1993). p.Arg83Cys is present in 50% of alleles in French and 
Tunisian patients (Barkaoui et al., 2007; Trioche et al., 2000), 
80% of Sicilian and 100% of alleles in Ashkenazi Jewish 
patients (Ekstein et al., 2004; Stroppiano et al., 1999). This 
variant is found in genomAD in a frequency of 0.0005 (Lek 
et al., 2016) and appears to be in a hotspot since two other 
variants are observed in the same position (p.Arg83His and 
p.Arg83=). There are another eight variants in amino acids 
80, 81, and 82, six of them being pathogenic. In the same 
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15% of alleles in GSD Ia. They both represent approximately 
54% of variants found in GSD Ia patients.
The second most frequently found variant among all pa-
tients was p.Leu348Valfs in SLC37A4 gene, present in 10% 
of patients, and 47.7% of alleles (21/44 alleles) in GSD Ib. 
This variant was present in 39% of Serbians patients (Skakic 
et al., 2018) and 31% of White patients reviewed in Chou, 
Jun, and Mansfield (2010).
Twenty‐seven novel variants were identified among the 
125 patients, observed mainly among patients with GSD type 
III and type IX. AGL, that causes GSD III, is one of the larg-
est genes, and has the highest number of variants reported 
in HGMD – The Human Gene Mutation Database (Stenson 
et al., 2003), which proves its heterogeneity. The increased 
number of variants in type IX patients can be justified by 
their lower characterization.
Some of the novel variants have already been detected in 
database projects involving the search for variants in a large 
number of individuals but never related to patients. We inves-
tigate the variants in “The Exome Aggregation Consortium” 
– ExAC – composed of 60,706 unrelated individuals, and the 
Online Archive of Brazilian Mutations – AbraOM – composed 
of 609 elderly individuals, as in other databases (Lek et al., 
2016; Naslavsky et al., 2017; Sabeti, 2015). Seven of 27 novel 
variants were in ExAC, all in very low frequencies (Table 2).
Seven different types of GSDs were found. Only types 0, 
IV, XI and XII were not observed among the 125 patients. 
The type IX represented 22.4% of the patients (12.8% of 
type IXa), since GSD type IX had never been described in 
Brazilian patients.
In two patients, only one variant was found (patients 84 
and 85) instead of two. Both patients presented variants in 
AGL. This gene has the highest number of gaps in coverage of 
NGS and is one of the biggest genes in panel, with 36 exons. 
However, the gaps were analyzed by Sanger sequencing and 
no variant was found. The results obtained from these patients 
are contradictory, since the variants found in both cases are 
described for GSD type III; however both patients presented 
inconsistent clinical findings. One of them has Down syn-
drome and liver histology similar to GSD III, but no biochem-
ical results are compatible with the disease and the patient 
does not present any clinical symptoms. The other patient 
presented hypoglycemia from birth, however, currently asso-
ciated with hyponatremia and metabolic acidosis. The liver bi-
opsy was inconclusive and not suggestive of GSD. Therefore, 
it is possible that variants or technical artifacts are eliminating 
the amplification of the mutated allele or the variants are in 
regulatory regions, not covered by the panel, but the absence 
of disease is a possibility (Hedell, Dufva, Ansell, Mostad, & 
Hedman, 2015; Inokuchi et al., 2016).
In five patients with no identified variants, the clinical 
suspicions are mild or inconclusive, once they did not have 
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the diagnosis of GSD, besides hypoglycemia and/or hepato-
megaly. The NGS was a diagnostic exclusion test; therefore, 
it was an expected result. These patients probably do not have 
GSD, once hepatomegaly and hypoglycemia are difficult to 
distinguish from other metabolic storage disorders without 
more clinical findings. Another possibility is the presence of 
variants in nontargeted deep intronic and regulatory regions 
(Wang et al., 2013).
Relationships of synergistic heterogeneity should be 
considered for GSDs, since the disease‐causing deficient 
enzymes share metabolic pathways, however it was not ob-
served in the present study (Vockley, Rinaldo, Bennett, 
Matern, & Vladutiu, 2000).
The patient 120 is possibly a GSD patient because he pre-
sented clinical symptoms such as hypoglycemia and keton-
uria but no other clinical signs, however only synonymous 
variants were found in GYS2 (that causes GSD type 0), which 
does not justify the disease.
This variety of results reflects the profile of an extremely 
large country with an interesting and important mix of peo-
ple from all over the world. The presence of immigrants 
from the most diverse origins, such as Africans, Asians, and 
Amerindians justifies the variability of alleles found in a 
highly mixed population. Genetic analyses indicate that Latin 
Americans trace their ancestry mainly in the intermixing of 
Native Americans, Europeans, and Sub‐Saharan Africans. 
Historically, Latin America has a continuous, differential, 
and diverse intra‐ and intercontinental migration events, and 
presents higher prevalence of metabolic diseases (Adhikari, 
Chacón‐Duque, Mendoza‐Revilla, Fuentes‐Guajardo, & 
Ruiz‐Linares, 2017; Chacón‐Duque et al., 2018; Giolo et al., 
2012; Quinto‐Sánches et al., 2017; Resque et al., 2016).
Among the advantages of NGS diagnosis, patients 
undiagnosed by traditional means were investigated and 
correctly diagnosed in the present study. This method is 
especially promising for mixed populations with high level 
of heterogeneity. This method also allows the identification 
of unexpected diagnoses in the supposed typical pheno-
types. Rare genetic diseases can be a diagnostic challenge, 
sometimes an odyssey. The NGS technologies can provide 
a fast diagnosis, advantages for treatment management, in 
reproductive choices, genetic counseling, and fertility ser-
vices (Schofield et al., 2017). The GSD traditional diag-
nosis methods involve liver biopsy, an invasive and risked 
method, that can be avoided with a well‐established mo-
lecular method (Bali, Chen, Austin, & Goldstein, 2016; 
Lévesque et al., 2016).
This diagnosis is an important advancement for patients 
with nontypical forms of disease, especially for those who 
need agile actions, since it evaluates 11 genes at the same 
time.
This was an important step to increase the knowledge 
about the genetics of the different types of hepatic GSDs 
in Brazilian patients, since they have a genetically het-
erogeneous origin, and it is reflected in the variability of 
types and variants (Vega et al., 2016; Wang et al., 2013). 
The evaluation by NGS also allows to detect cases of syn-
ergic heterogeneity that cannot be perceived by Sanger 
sequencing.
Differentiated therapeutic management among GSD justi-
fies the population characterization of patients. If NGS anal-
yses are not available or expensive, the molecular diagnosis 
should be conducted first through the search for the patho-
genic variants p.Arg83Cys and p.Gln347* in G6PC in case 
of GSD Ia or p.Leu348Valfs in SLC37A4 for GSD Ib. Sanger 
sequencing approach is the most cost‐effective to solve up 
to 40% of the cases. However, for the cases without preva-
lent mutations or without suspected type of GSD, NGS is the 
most effective solution.
This study emphasizes that molecular genetic analysis is a 
reliable and convenient alternative to the assay of enzymatic 
activity in a fresh liver biopsy specimen for the diagnosis of 
GSDs. This type of study is an important tool for the estimation 
of disease progression, since different types of GSDs present 
variations in their clinical course and treatment, besides serv-
ing as a basis for genetic counseling and prenatal diagnosis.
The discovery of a significant number of new mutations 
reinforces the allelic variability of different GSDs and 
proves that the diagnosis of GSDs in Brazil can be chal-
lenging, showing the validity of NGS gene panel use for 
diagnosis.
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